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Alzheimer’s disease (AD) is characterized pathologically by the deposition of β-amyloid
peptides (Aβ) and the accumulation of neurofibrillary tangles (NFTs) composed of hyper-
phosphorylated tau. Regardless of the pathological hallmarks, synaptic dysfunction is
widely accepted as a causal event in AD. Of the two major types of synapses in the
central nervous system (CNS): glutamatergic and GABAergic, which provide excitatory
and inhibitory outputs respectively, abundant data implicate an impaired glutamatergic
system during disease progression. However, emerging evidence supports the notion
that disrupted default neuronal network underlies impaired memory, and that alterations
of GABAergic circuits, either plays a primary role or as a compensatory response to
excitotoxicity, may also contribute to AD by disrupting the overall network function.
The goal of this review is to provide an overview of the involvement of Aβ, tau and
apolipoprotein E4 (apoE4), the major genetic risk factor in late-onset AD (LOAD), in
GABAergic neurotransmission and the potential of modulating the GABAergic function
as AD therapy.
Keywords: GABAergic neurotransmission, amyloid beta-peptides, tau proteins, apolipoproteins E, neuronal
inhibition
INTRODUCTION OF ALZHEIMER’S DISEASE
Alzheimer’s disease (AD) is the most common age-associated neurodegenerative disorder, which is
characterized by the deterioration of memory and cognition. About 10% of the population over the
age of 65 and 30–50% of the population over the age of 85 suffer from AD (Querfurth and LaFerla,
2010). Despite significant research and drug development effort in the past decades, currently there
are no effective therapies that can prevent, delay or stop the progression of AD, causing a severe
burden for the patients, their families and the society.
A small subset (less than 2%) of AD cases result from dominantly inherited genetic
mutations in genes encoding the β-amyloid precursor protein (APP) and presenilins (PSEN1
and PSEN2, Goate et al., 1991; Levy-Lahad et al., 1995; Sherrington et al., 1995). These AD
cases usually develop disease before the age of 60, referring as early-onset familial AD (FAD).
Sporadic or late-onset AD (LOAD) usually develops the disease later in life, representing
the majority of AD cases (Kanekiyo et al., 2014). The pathological hallmarks of AD include
widespread neuronal degeneration, senile plaques and intracellular neurofibrillary tangles
(NFTs; Glenner and Wong, 1984; Querfurth and LaFerla, 2010; Tapia-Rojas et al., 2015).
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β-Amyloid
The extracellular senile plaques are composed of accumulated
small peptides called β-amyloid (Aβ) derived from the sequential
cleavage of APP. There are three major isoforms of APP
resulting from alternative splicing, named as APP695, APP751
and APP770 according to their number of amino acid residues.
The isoform APP695 is predominantly expressed in neurons and
lacks a 56 amino acid Kunitz Protease Inhibitor (KPI) domain
at extracellular region (Goate et al., 1991; Zhang et al., 2012;
Guzmán et al., 2014; Gautam et al., 2015). Full-length APP is
a type I transmembrane protein and can undergo sequential
proteolytic cleavage by distinct α-, β- or γ-secretase.
Depending on whether there’s toxic Aβ generation, the APP
proteolytic cleavage is divided into two types: amyloidogenic
processing and nonamyloidogenic processing. In amyloidogenic
processing, APP is first cleaved by β-secretase (beta-site APP
cleaving enzyme 1, BACE1), releasing a soluble ectodomain
called sAPPβ. The remaining membrane associated carboxyl
terminal fragment (βCTF) will be further cleaved by γ-secretase
within the cell membrane, releasing neurotoxic Aβ peptides
and amyloid intracellular domain (AICD; Li et al., 2014;
Ohki et al., 2014; Jung et al., 2015; Neumann et al., 2015;
Sadleir et al., 2015; Zhang et al., 2015). The exact cleavage
site of γ-secretase may vary inside membrane, yielding Aβ
peptides with 36–43 amino acids. Among them, Aβ40 is
the major form while Aβ42 is the more amyloidogenic and
toxic form (Querfurth and LaFerla, 2010; Zhang et al., 2012;
Buggia-Prévot et al., 2014). The AICD tail released inside
cytoplasm has been demonstrated to target the nucleus and
regulate gene transcription activity (Querfurth and LaFerla,
2010).
As imbalance between production and clearance occurs,
Aβ peptides could spontaneously self-aggregate into soluble
oligomers, or further grow into insoluble fibers and finally
amyloid plaques. The ‘‘amyloid hypothesis’’ is based on the
idea that the accumulation of Aβ may be the initiating
factor of AD pathogenesis. Multiple lines of evidence have
indicated that accumulation of Aβ lead to a neurodegenerative
cascade, resulting in synaptic dysfunction, NFT formation
and eventually neuronal loss in vulnerable brain regions
including cortex and hippocampus (Selkoe, 1998; Hu et al.,
2014; Stancu et al., 2014). Compared to insoluble fibers,
the soluble Aβ oligomers are more neurotoxic and confer
the most deterious effect of Aβ (Querfurth and LaFerla,
2010; Zhang et al., 2012; Tu et al., 2014; Xu et al.,
2015).
The nonamyloidogenic processing of APP initiates from the
proteolytic cleavage by α-secretase, releasing a soluble sAPPα
(Postina, 2012; Jiang et al., 2014;Wang et al., 2014). It is 16 amino
acids bigger than sAPPβ because the cleavage site of α-secretase
is within the Aβ domain, therefore excluding the possibility of
Aβ generation. The membrane remaining αCTF could be further
cleaved by γ-secretase, releasing the shorter P83 peptide and
AICD. In contrast to Aβ, sAPPα showed important protective
roles in neuronal survival and synaptic plasticity against Aβ
(Mattson et al., 1993; Goodman and Mattson, 1994; Yamamoto
et al., 1994; Furukawa and Mattson, 1998).
Tau
The major component of AD hallmark NFTs was revealed to
be abnormally hyperphosphorylated microtubule-associated
protein tau (MAPT), which is essential for assembly
and stabilization of microtubules (Spillantini and Goedert,
1998; Querfurth and LaFerla, 2010). The encoding gene of
MAPT is located on chromosome 17 in human and expresses six
isoforms by alternative splicing in central nervous system (CNS).
As a result, the six tau isoforms possess variable N-terminal
repeats (0, 1 or 2N) and C-terminal microtubule-binding
domains (3 or 4R; Kolarova et al., 2012; Caillet-Boudin et al.,
2015; Song et al., 2015).
In physiological conditions, tau is very soluble and mainly
located in neuronal axons, where it binds microtubules
and regulates the axonal transportation for vesicles and
organelles. Since many amino acid residues of the tau
protein are potential phosphorylation sites (Ser, Thr,
or Tyr), tau is highly phosphorylation-labile (Hasegawa
et al., 1992; Hanger et al., 2009). It dynamically switches
between phosphorylated and dephosphorylated state during
each cell cycle (Pedersen and Sigurdsson, 2015; Wang
et al., 2015). It has been demonstrated that increasing
tau phosphorylation reduces its affinity for microtubules
(Iqbal et al., 2005). The imbalance between tau kinase and
phosphatase activities under phathological conditions could
lead to tau hyperphosphorylation, which makes tau insoluble
and self-aggregate into paired helical filament structure of
NFTs. In NFTs, at least 7–8 residues were phosphorylated
(Hasegawa et al., 1992; Hanger et al., 2009; Mandelkow and
Mandelkow, 2012; Marttinen et al., 2015). Hyperphosporylated
tau lacks the affinity for microtubules, therefore making
microtubules unstable and impairing their critical function
in axonal transportation, eventually resulting in synaptic
dysfunction.
The specific tau pathology was reported to correlate well
with cognitive abilities. In the cerebrospinal fluid (CSF) of AD
patients, the levels of both total tau and phosphorylated tau were
found increased (Jack et al., 2013). Besides AD, NFTs composed
of hyperphosphorylated tau was found to be a common
pathological feature in a number of neurodegenerative disorders
including Parkinson’s disease, frontotemporal dementia and
progressive supranuclear palsy (PSP), referring as a class of
neurodegenerative diseases called tauopathies (Spillantini and
Goedert, 1998; Lonskaya et al., 2014; Golovyashkina et al., 2015;
Yamada et al., 2015). Considering the critical contribution of tau
to the pathological progression of AD, a tau based hypothesis for
AD has received wide notice. It emphasizes that the intracellular
aggregation of hyperphosphorylated tau leads to the disassembly
of microtubules, collapse of synapses, and eventually the cell
death in AD (Pedersen and Sigurdsson, 2015).
INTRODUCTION OF GABAergic
NEUROTRANSMITTER SYSTEM
γ-aminobutyric acid (GABA) is the principle inhibitory
neurotransmitter in mammalian CNS. The inhibitory
effect of GABA can be conferred through three distinct
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receptor subfamilies named GABAA, GABAB and GABAC
receptors. Both GABAA and GABAC receptors are ligand-
gated chloride (Cl−) channels, whereas GABAB receptors
are G-protein coupled metabotropic receptors (Chebib and
Johnston, 1999; Bormann, 2000). In the vertebrate brain,
GABAA receptors mediate the majority of fast inhibition
in the brain. They are composed of five distinct subunits
pentamerically assembled, forming a ligand-gated Cl− ion
channel. According to their gene identity, the identified
GABAA receptor subunits are classified as α1–6, β1–3, γ1–3,
ρ1–3, θ, δ, pi and e. In the mammalian brain, the most
common combination of GABAA receptor contains two α,
two β and one γ subunits. GABAC receptors are composed
of ρ1–3 subunits, form homomeric or heteromeric channels,
making them distinct from GABAA receptors in pharmacology
and function (Johnston, 1994; Lüscher and Keller, 2004).
GABAA receptors are widely expressed in all the CNS,
while GABAC receptors are highly enriched in retina. Since
both GABAA and GABAC receptors are ligand-gated Cl−
channels, sometimes we also consider GABAC receptors as a
minor subgroup in GABAA receptors (Barnard et al., 1998).
GABAB receptor is a metabotropic receptor coupling with Gi/o
protein. It regulates neuronal activity by either opening the
K+ channel or inhibiting Ca2+ channel via the Gi/o protein-
dependent signaling cascade (Bowery, 1989; Marshall et al.,
1999).
In CNS, the inhibitory action of GABA can be broadly
divided into two classes: phasic inhibition and tonic inhibition
(Farrant and Nusser, 2005; McQuail et al., 2015). In GABAergic
interneurons, neurotransmitter GABA is synthesized from
glutamate by the enzyme glutamic acid decarboxylase (GAD).
Synthesized GABA is transported along the axon to presynaptic
terminals and recruited into vesicles by the vesicular GABA
transporter (vGAT; Glykys and Mody, 2007; Gonzalez-Burgos
et al., 2009). Upon membrane depolarization induced by
action potential, neurotransmitter GABA can be released
from presynaptic vesicles into the synaptic cleft, resulting in
the burst increase of GABA concentration in the cleft. Most
of the released neurotransmitter GABA transiently activates
specific GABA receptors on postsynaptic membrane and results
in the phasic inhibition of postsynaptic neurons. The phasic
inhibition has been demonstrated to be mainly mediated
by GABAA receptors contains γ2 subunits postsynaptically
(Schweizer et al., 2003; Farrant and Nusser, 2005). Tonic
inhibition refers to the sustained form of inhibition upon
neuronal cells. Beyond binding to postsynaptic receptors,
released neurotransmitter GABA also spills over from synaptic
cleft and activates GABA receptors at extrasynaptic area. Tonic
inhibition has been demonstrated to be mainly mediated
by extrasynaptic GABAA receptors containing pi subunit
in most brain regions, and GABAA receptors containing
α5 subunit especially in hippocampus (Glykys et al., 2008).
Recently evidence also indicates the participation of astrocytes
and GABAB receptors in tonic inhibition. Especially under
pathological conditions, reactive astrocytes release GABA
through Bestrophin 1 (Best1) channel. The released GABA
could activate both GABAA and GABAB receptors at
extrasynaptic area and confer inhibitory effect (Wu et al.,
2014).
GABAergic NEUROTRANSMISSION IN THE
PATHOGENESIS OF AD
Alteration of GABAergic
Neurotransmission in AD
In the past, considerable research has focused on themechanisms
of calcium permeable excitatory acetylcholine receptor or
glutamate receptors including NMDA and AMPA receptors
in AD. Compared to the marked deficits seen in excitatory
cholinergic and glutamatergic systems, much less consistent
results were revealed for GABAergic system, the main inhibitory
neurotransmission in brain. Early studies in postmortem human
brains or using animal models concluded that GABAergic
neurons and receptors appear more resistant to AD pathology,
with only modest loss in AD (Rossor et al., 1982). However,
during recent years this statement has been challenged
with accumulating evidence, indicating that GABAergic
neurotransmission also undergoes profound pathological
changes in AD and may be a promising therapeutic target for
this neurodegenerative disorder (Figure 1).
By using HPLC, the concentrations of different
neurotransmitters were measured in the brain of AD patient
samples and age-matched control subjects. In the temporal
cortex of AD patients, significantly lower levels of GABA
and glutamate neurotransmitters were observed, indicating
deficient synaptic function and neuronal transmission in AD
(Gueli and Taibi, 2013). The decreased GABA neurotransmitter
levels were also observed in the CSF of AD patients and
normal humans with aging (Bareggi et al., 1982; Zimmer
et al., 1984; Grouselle et al., 1998). An immunocytochemistry
study showed diminished perisomatic GABAergic terminals in
brain sections from both AD patients and APP/PS1 transgenic
mice, especially on cortical neurons adjacent to amyloid
plaques, implicating the loss of GABAergic neuronal function
in AD (Garcia-Marin et al., 2009; Ramos-Miguel et al., 2015).
However, the alteration of synaptic function in AD appears more
complicated during the disease progression. By using 4-month
old tgCRND8 and 18-month old APP/PS1 transgenic mice
respectively, both glutamatergic and GABAergic presynaptic
terminals were found elevated at early stage, but declined at
late time point in the distinct AD mice models (Bell et al.,
2003, 2006; Bell and Claudio Cuello, 2006; Marttinen et al.,
2015).
In the nervous system, maintaining a proper dynamic
balance between the excitatory glutamate and inhibitory GABA
neurotransmitters is critical for neuronal function. Altered
synaptic balance was found to be one of the pathological
factors that contribute to neuronal disorders including AD,
Huntington’s disease and schizophrenia (Kehrer et al., 2008;
Cummings et al., 2009; Sun et al., 2009). Aβ themost well-studied
neurotoxic factor in AD pathogenesis, has been demonstrated
to be a pore-forming molecule. Similar to other pore-
forming neurotoxins, Aβ treatment induced perforation in cell
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FIGURE 1 | Proposed model of GABAergic signaling in AD pathogenesis. Calcium enters the presynaptic terminal via Aβ formed pores on cell membrane.
The increased calcium concentration triggers presynaptic glutamate neurotransmitter release and activates postsynaptic receptors. The activated NMDA receptors
further enhance the GABAA receptor activation to dampen the overexcitation. In astrocytes, GABA could be synthesized from putresine or glutamate and released
via GAT3/4 or Best1 channel. The release of GABA from astrocytes may be enhanced under AD conditions to activate the extrasynaptic GABAA and GABAB
receptors, resulting in suppressed long-term potentiation (LTP) and impaired cognition. The activation of GABAA receptors by anesthetics reduces PP2A binding with
tau protein, resulting in tau hyperphosphorylation, which feeds back and enhances the activation of GABAergic interneurons and GABA release. ApoE4 secreted
from GABAergic interneurons results in reduced interneuron number and reduced GABAergic innervation to other neurons, eventually leading to the disruption of
neuronal circuitry and impaired cognition.
membrane, causing a rapid increase of calcium influx in cultured
hippocampal neurons (Parodi et al., 2010; Sepulveda et al., 2010).
The increased intracellular calcium concentration triggered
the presynaptic neurotransmitter release, leading to disrupted
neuronal excitation. In the presence of low concentration of
Aβ, the frequency of electrophysiological recorded miniature
currents increased quickly, but decreased gradually after a couple
of hours, indicating the presynaptic vesicular depletion caused by
Aβ (Parodi et al., 2010).
A subset of AD patients have been reported to suffer from
epilepsy, which is a typical disorder resulting from imbalanced
neuronal excitation. In a study with transgenic human APP
(hAPP) mice, Aβ was demonstrated to cause aberrant neuronal
overexcitation and spontaneous nonconvulsive seizure activity
in cortical and hippocampal networks, the most vulnerable
brain regions in AD. The increased epileptic activities in
turn triggered downstream alterations including GABAergic
sprouting and increased synaptic inhibition in hippocampal
circuits. These alterations are characterized as compensatory
inhibitory mechanisms to ameliorate neuronal overexcitation
and keep the normal neuronal excitation (Palop et al., 2007).
The finding of direct crosstalk between postsynaptic glutamate
NMDA receptors and GABAA receptors further supported
the neuronal circuit remodeling mechanisms. In hypothalamic
neurosecretory neurons, the NMDA receptor activation by
endogenous glutamate was observed to evoke a transient
and reversible enhancement of postsynaptic GABAA receptors
(Potapenko et al., 2013). The inter-receptor crosstalk between
NMDA receptor and GABAA receptor was considered as a
compensatory mechanism for dampening the overexcitation
commonly observed in pathological conditions. While on the
other hand, the increased inhibitory function mediated by
GABAergic synapses may interfere with processes required for
learning and memory, as indicated by long-term potentiation
(LTP) deficits in dentate gyrus (Palop et al., 2007). Consistent
with this result, application of GABAA receptor antagonist
picrotoxin was demonstrated to prevent such LTP deficits
observed in animal model of AD (Kleschevnikov et al., 2004).
Alteration in postsynaptic GABAA receptors was also
observed along with AD pathology. Immunohistochemistry
study indicates that the β2/3 subunit was markedly preserved,
while α1 and γ subunits were upregulated in human AD subjects
(Mizukami et al., 1998; Iwakiri et al., 2009). By microtransplating
cell membrane isolated from temporal cortices of control and AD
patients into Xenopus oocytes, the level of transplanted GABAA
receptors were determined by electrophysiological recording.
The whole-cell currents mediated by transplanted GABAA
receptors were recorded (Limon et al., 2012). A reduction of
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GABA-evoked currents was observed in cells transplanted with
GABAA receptors from AD brains. In particular, the mRNA
and protein levels of α1 and γ2 subunits were found down-
regulated, whereas α2, β1 and γ1 subunits were up-regulated
in AD brains, indicating that GABAergic neurotransmission
undergoes a functional remodeling in the cortex of AD
patients.
Consistent results for the impact of Aβ on GABAA receptors
were obtained in cerebellum. In cultured rat cerebellar granule
neurons (CGNs), treatment of recombinant Aβ40, rather than
Aβ42, significantly increased the expression level of α6 subunit
containing GABAA receptors and their functional recorded
currents. In addition, the expression level of α6 protein in
APP knockout mice was significantly lower than in WT CGNs.
Further investigation demonstrated that Aβ could induce the
phosphorylation of ERK and mTOR, resulting in the increased
translation of GABAA receptor α6 subunit (Zhan et al., 2014).
The elevated inhibition mediated by GABAergic
neurotransmission found in AD mice models do not appear
to be consistent with results obtained from AD patients. Even
though transgenic mice models have been widely used for AD
mechanism investigation, it should be noted that they may not
completely represent the complex pathologic characteristics of
AD. It should also be noticed that the transgenic mice used in
these studies were with various ages, between 4– to 11-month
old, at which age even the amyloid plaques were observed, the
neuronal death was not detectable (Jo et al., 2014). AD is by
far one of the most complicated progressive neurodegenerative
disorders. The differential results indicate that at various stages
of the disease, GABAergic system might undergo dynamic
remodeling and play different roles in AD pathology.
Alteration of GABAergic Gliotransmission
in AD Mice Models
It’s well known that astrocytes are important for uptake and
recycling of specific neurotransmitters including GABA and
glutamate. In CNS, not only neurons, but also astrocytes were
found to be able to produce and release GABA, activating
GABAA and GABAB receptors in nearby neurons (Yoon et al.,
2012; Yoon and Lee, 2014). Recently, several studies indicate that
astrocytes activated by Aβ could release GABA and participate
in AD pathology (Mitew et al., 2013; Jo et al., 2014; Wu et al.,
2014).
In APP/PS1 and 5× FAD mice, significantly more astrocytes
were found activated in hippocampus. Normally astrocytes in
wild type mice showminimal GABA immunoreactivity. While in
AD mice models, reactive astrocytes were found to abundantly
produce and release inhibitory GABA gliotransmitter. As a
consequence, HPLC analysis with collected interstitial fluid
samples from dentate gyrus revealed significantly elevated GABA
level in APP/PS1 mice than wild-type littermates (Jo et al.,
2014). In the hippocampus of 5× FAD, the GABA, glutamate
and GAD immunostaining intensity were dramatically elevated
in astrocytes (Wu et al., 2014). In the synaptosomes isolated
from cortex of aged APP/PS1 mice with high amyloid load, the
protein level of GAD was found significantly higher than in wild
type control and plaque-free region cerebellum. Further study
revealed that the increased GAD activity was localized in isolated
glial synaptosome, rather than neuronal synaptosome, suggesting
that in APP/PS1 transgenic mice, Aβ plaques stimulate the
astrocytic GABA synthesis and release (Mitew et al., 2013).
In astrocytes, there may exist more than one pathways for
the synthesis and release of GABA. In APP/PS1 mice, the
GABA gliotransmitter in astrocytes was demonstrated to be
synthesized from putrescine by enzyme monoamine oxidase-B
(MaoB) and was released from astrocytes via Best1 channel.
The immunoactivity of GABA and MaoB in astrocytes were
abnormally and strongly upregulated in the dentate gyrus of
APP/PS1 mice and the postmortem brain of AD patients,
especially around Aβ plaques (Jo et al., 2014). While in the study
with 5× FAD mice, the increased GABA gliotransmitter was
synthesized from glutamate by enzyme GAD, and released from
astrocytes via the specific GABA transporter GAT3/4 (Wu et al.,
2014). The upregulated GABA release from astrocytes could bind
to extrasynaptic GABAA and GABAB receptors, strongly inhibit
synaptic function and finally leads to the memory and cognitive
deficits in AD (Jo et al., 2014).
Linkage between Tau and GABAA
Receptors
GABAA receptor is the most well-known pharmacological target
for anesthetics including isoflurane, pentobarbital, propofol and
chloral hydrate. In recent years, studies indicate that general
anesthesia may contribute to the development and exacerbation
of AD (Whittington et al., 2013). Besides Aβ plaques, NFTs
composed of hyperphosphorylated tau protein is the most
important pathological hallmark of AD. Both pre-clinical and
clinical studies have found that anesthesia significantly increase
the phosphorylation of tau protein. (Le Freche et al., 2012;
Whittington et al., 2013). Since GABAA receptor is the major
pharmacological target of most anesthetics, the activation
of GABAA receptors was assumed and later confirmed to
participate in the anesthesia-induced tau hyperphosphorylation.
By using a live cell reporter system, the direct protein
interaction between tau and peptidyl-prolyl cis-transisomerase 1
(Pin1) was identified (Nykänen et al., 2012). Pin1 controls the
access of phosphatases to serine-proline or threonine-proline
(SP/TP) sites of tau, and therefore promotes dephosphorylation
of tau via protein phosphatase 2A (PP2A). Interestingly, with
pharmaceutical chemical library screening, several GABAA
receptor modulators including anesthetics benzodiazepines
and barbiturates were found to increase the interaction
between tau and Pin1, but significantly promoted the
phosphorylation of tau. Further study revealed that these
GABAA receptor modulators do not directly inhibit the
activity of PP2A, but recruited more PP2A to cell surface
for GABAA receptor β3 subunit dephosphorylation and
receptor desensitization, therefore reduced the availability of
PP2A for tau dephosphorylation. GABAA receptor activation
significantly increased tau phosphorylation at AT8 epitope
(Ser199/Ser202/Thr205) in cultured cortical neurons (Nykänen
et al., 2012).
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On the other hand, the hyperphosphorylated tau also has
influence on GABAergic synapses. In tau P301L transgenic mice,
in which the extent of tau phosphorylation was remarkably
upregulated, the GABAergic interneurons were observed
hyperactivated, leading to increased GABA neurotransmitter
level in the brain (Nilsen et al., 2013).
Overall, GABAA receptor activation could enhance tau
phosphorylation by reducing the association of PP2A with tau,
consequently increase the intracellular NFTs in neurons
and contribute to the development of AD. Vice versa,
the hyperphosphorylated tau could enhance GABAergic
neurotransmission. There might be a feedback loop between
GABAA receptor activation and tau phosphorylation in nervous
system (Figure 1).
Contribution of GABAergic Interneurons in
apoE4-Induced Deleterious Effect
Apolipoprotein E4 (apoE4), the major genetic risk factor
for AD, accounts for 60–75% of all AD cases, increasing
significantly the risk of AD and lowering the age of onset of
this disorder (Hu et al., 2015; Liu et al., 2015). By using mice
model knockout of endogenous Apoe and knockin with various
human APOE alleles, the neurogenesis was found reduced
in both apoE knockout and human apoE4 knockin mice,
leading to impaired learning and memory. In apoE4 knockin
mice, the GABAergic interneuron number and presynaptic
GABAergic input to newly born neurons both decreased,
which was associated with increased tau phosphorylation
and neurotoxic apoE4 fragments. Treatment with GABAA
receptor agonist pentobarbital restored the neurogenesis
deficit in apoE4 knockin mice. Consistently, treatment
of apoE3 knockin mice with GABAA receptor antagonist
picrotoxin decreased the neurogenesis in hippocampus
(Li et al., 2009). These findings suggest that the activation
of GABAA receptors and GABAergic signaling pathway could
be targeted to mitigate the deleterious effects of apoE4 on
neurogenesis.
ApoE is expressed in various cell types. In the brain, apoE
is mainly released from astrocytes, increasing during aging. It
could also be released from neurons, increasing with stress and
injury (Huang, 2010; Huang and Mucke, 2012; Mahley and
Huang, 2012). Dr. Huang’s group generated specific human
APOE allele knockin mice models, in which the human APOE
gene in knockin mice was conditionally deleted in astrocytes,
neurons or specific GABAergic interneurons. Deleting apoE4
in neurons, but not in astrocytes, rescued the apoE4-induced
deficits including GABAergic interneuron loss and impaired
learning andmemory. In addition and importantly, conditionally
deleting apoE4 in GABAergic interneurons was sufficient to
have similar effect and completely prevented the apoE4-induced
deficits (Knoferle et al., 2014), suggesting that the apoE4 sourced
from GABAergic interneurons is responsible for the deleterious
effect of apoE4 on neuronal loss and cognitive deficit.
In human apoE4-positive AD individuals were found often
associated with elevated Aβ levels, and Aβ has been shown
to impair GABAergic neurotransmission (Huang and Mucke,
2012; Verret et al., 2012). Mice expressing human apoE4
knockin and human APP FAD transgene (apoE4-KI/hAPP-
FAD) exhibited high Aβ level and severe cognitive deficit
(Palop et al., 2007; Verret et al., 2012). Embryonic interneuron
progenitors transplanted into the hilus of apoE4 knockin and
apoE4-KI/hAPP-FAD mice successfully developed into mature
interneurons that release inhibitory neurotransmitter GABA.
In addition, the recovered hippocampal circuitry functionally
restored normal learning and memory (Tong et al., 2014),
highlighting the importance of GABAergic interneuron and
GABAergic neurotransmission in AD pathogenesis.
Interestingly apoE4 also showed sex-dependent
characteristics. The risk of developing AD is significantly
higher in APOE4 carrying females than males. Studies found
that in female apoE4 knockin mice, the GAD67 or somatostatin
positive GABAergic interneuron number decreased in an age-
dependent manner, accompanied by spatial learning deficits. The
ratio of hilar inhibitory GABAergic interneurons to excitatory
mossy cells also decreased. However, in male apoE knockin
mice, such ratio was kept consistent, regardless of various apoE
genotype and age. Furthermore, in aged male apoE knockin
mice, the number of hilar GABAergic interneurons even
increased, independent of APOE genotype (Leung et al., 2012).
These findings suggest that the sex-dependent effect of apoE4 on
AD developing risk is at least partially mediated by its differential
effects on GABAergic function.
All together, the reported data strongly suggest that
GABAergic interneuron plays critical roles in the deleterious
effect of apoE4. ApoE4 expressed in GABAergic interneurons
may result in apoptosis of these interneurons, leading to reduced
GABAergic innervation to other neurons, and disruption of the
inhibitory/excitatory balance and neuronal network (Figure 1).
The expression of apoE4 was found to cause hyperactivity in
human hippocampus (Filippini et al., 2009), which is consistent
with the disrupted inhibitory signaling system.
POTENTIAL GABAergic THERAPIES
FOR AD
Intense therapeutic effort has been taken in the AD field, but
the outcomes have been disappointing. As outlined in this
review, multiple lines of evidence have strongly suggested that
GABAergic neurotransmission plays very important roles in
AD pathogenesis. There’s close linkage between GABAergic
signaling system and various aspect of AD pathology including
Aβ toxicity, tau hyperphosphorylation and apoE4 effect.
Accordingly GABAA andGABAB receptormodulators have been
investigated in preclinical or clinical tests (Table 1).
GABAA Receptor Agonists
Hyperexcitation of neuronal activity has been observed in AD
brain and was considered one of the toxic factors leading
to neuronal death. GABAergic neurotransmission was found
upregulated in the hippocampus of AD mice models before
general cell death (Jo et al., 2014; Wu et al., 2014), which
is possibly a neuronal mechanism to neutralize the abnormal
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TABLE 1 | Effect of GABAergic chemicals in AD models.
Name Type Effect Reference
Etazolate (EHT-0202) GABAA receptor agonist Protected neurons again Aβ-induced toxicity,
increased the protein level of sAPPα, displayed
anti-inflammation effect after traumatic brain
injury and improved cognition in mice models.
Marcade et al. (2008), Drott
et al. (2010), Vellas et al.
(2011) and Siopi et al.
(2013)
Muscimol GABAA receptor agonist Inhibited Aβ25–35-induced apoptotic death in
neurons.
Lee et al. (2005)
Propofol GABAA receptor agonist Decreased Aβ generation and accelerated Aβ
degradation, reduced the levels of Aβ40 and
Aβ42 in aged mice brain. Improved cognitive
function and attenuated caspase-3, caspase-9
activation in AD mice model.
Shao et al. (2014) and
Zhang et al. (2014)
MRK-016, α5IA, α5IA-II Inverse agonists of GABAA
receptor α5 subunit
Improved cognition in animal models. Dawson et al. (2006), Atack
et al. (2009), Atack (2010)
and Guerrini et al. (2013)
CGS9896 Inverse agonists of GABAA
receptor α5 subunit
Enhanced the murine memory task. Guerrini et al. (2009)
Ro-4938581, Ro-4882224 Inverse agonists of GABAA
receptor α5 subunit
Reversed the scopolamine-induced impairment
in working memory.
Knust et al. (2009)
SGS742 (CGP36742) GABAB receptor antagonist Improved attention and working memory in
animal models and patients with mild cognitive
impairment, increased the levels of NGF and
BDNF in rats.
Getova and Bowery (2001),
Froestl et al. (2004) and
Helm et al. (2005)
CGP55845 GABAB receptor antagonist Improved cognition in rat model. Cryan and Kaupmann
(2005) and Lasarge et al.
(2009)
hyperexcitation. Some GABAA receptor agonists have been
tested and displayed promising effect.
Etazolate, the GABAA receptor modulator, has been shown
to exert neuroprotective effect against Aβ toxicity, anti-
inflammation after traumatic brain injury and improvement of
cognition (Marcade et al., 2008; Drott et al., 2010). Further
investigation revealed that etazolate exerted its neuroprotective
effect by activating GABAA receptor and stimulating α-
secretase cleavage of APP. The neuroprotective effect of
etazolate could be fully blocked by GABAA receptor antagonist.
Both in rat cortical neurons in vitro and in guinea pigs
in vivo, treatment with etazolate significantly increased the
protein level of sAPPα, whose neuroprotective effect has been
well demonstrated (Marcade et al., 2008). There might be
a relationship between GABAA receptor signaling and the
α-secretase cleavage pathway of APP. Etazolate (EHT-0202) has
entered Phase II clinical trial for the treatment of AD, with an
encouraging result on safety and patient tolerance (Vellas et al.,
2011).
Beneficial results have also been obtained with two GABAA
receptor agonists, muscimol and propofol (Shao et al., 2014;
Zhang et al., 2014). In cultured rat cortical neurons, pretreatment
of muscimol significantly inhibited Aβ25–35-induced neuronal
apoptotic death. GABAA receptor antagonist bicuculine
completely blocked the neuroprotective effect of muscimol
(Lee et al., 2005). Chronic treatment of aged mice (18-month
old) with propofol reduced the levels of Aβ40 and Aβ42 in
brain tissue. In addition, decreased expression of BACE1,
the critical enzyme for Aβ generation, and increased level of
neprilysin, the primary enzyme for Aβ degradation, were both
observed after propofol treatment (Zhang et al., 2014), indicating
that chronic activation of GABAA receptor by propofol plays
neuroprotective role against Aβ by decreasing Aβ generation
and accelerating Aβ degradation. Further investigation showed
that propofol treatment also improved cognitive function and
attenuated caspase-3, -9 activation in both WT and APP/PS1
mice (Shao et al., 2014). All these results support the notion
that GABAA receptor activation might have neuroprotective
function against Aβ and could effectively improve cognitive
function.
Inverse Agonists of GABAA Receptor α5
Subunit
GABAA receptor is a pentamer containing various allosteric
binding sites. It has been suggested that different subunits of
GABAA receptor may exert relatively distinct function. For
example, α1 subunit is mainly responsible for the sedative action
of diazepam, α2 subunit mediates the anxiolytic-like action,
whereas α5 subunit may be associated with cognition and
memory (Gabriella and Giovanna, 2010). It’s reported that α5
subunit deficiency enhanced hippocampus-dependent memory
and spatial learning ability in mice (Collinson et al., 2002;
Crestani et al., 2002). In addition, GABAA receptors containing
α5 subunit was found upregulated in the dentate gyrus of 5×
FADmice, and has been suggested tomediate the tonic inhibition
in CNS. A series of compounds have been developed, serving as
inverse agonists of GABAA receptor α5 subunit, which bind to
α5 subunit with much higher affinity than other subunits, but
negatively regulate receptor activity.
Frontiers in Aging Neuroscience | www.frontiersin.org 7 February 2016 | Volume 8 | Article 31
Li et al. GABAergic Neurotransmission in Alzheimer’s Disease
In the early 2000s, the Merck Sharp and Dohme identified
a series of benzothiophene derivatives with a notable binding
selectivity for GABAA receptor α5 subunit. Among them the
ligands MRK-016, α5IA and α5IA-II, all of which displayed
encouraging effect on cognition in animal models. The
compound α5IA has further advanced to preclinical and clinical
studies (Dawson et al., 2006; Atack et al., 2009; Atack, 2010;
Guerrini et al., 2013).
Another series of pyrazolo [5, 1-c] [1, 2, 4] benzotriazine
5-oxide (CGS9896) derivatives that are closely correlated to
α5IA-II also showed important activity in enhancing the
murine memory task (Guerrini et al., 2009). Other two
compounds Ro-4938581 and Ro-4882224 from Hoffmann-
La Roche Company were shown to significantly reverse the
scopolamine-induced working memory impairment. Supported
by this result, these two compounds Ro-4938581 and Ro-4882224
have been selected as candidates for further clinical studies
(Knust et al., 2009).
GABAB Receptor Antagonists
In AD mice models and human AD patients, GABA released
from activated astrocytes was significantly increased. The
released GABA could bind to neuronal GABAB receptors at
extrasynaptic area, and in turn participate in the inhibition of
synaptic release in APP/PS1 mice (Jo et al., 2014). To alleviate the
inhibition of synaptic function and improve the cognition deficit
in AD, several compounds served as GABAB receptor antagonists
have been tested.
SGS742 (CGP36742) is the first GABAB receptor antagonist
tested in clinical trials for AD treatment. In rodents and Rhesus
monkeys, SGS742 displayed pronounced cognition enhancing
effects in various cognitive and learning tasks. It blocked
the inhibitory postsynaptic potential (IPSP) and paired-pulse
inhibition (PPI) in hippocampus both in vitro and in vivo. It
also increased the mRNA and protein levels of NGF (nerve
growth factor) and BDNF (brain derived neurotrophic factor)
in cortex and hippocampus of rats (Froestl et al., 2004). In
addition, SGS742was well tolerated in both experimental animals
and human volunteers. In a Phase II study, oral administration
of SGS742 for 8 weeks significantly improved attention and
working memory in patients with mild cognitive impairment
(Getova and Bowery, 2001; Froestl et al., 2004; Helm et al.,
2005). These encouraging findings make SGS742 a promising
candidate for dementia treatment and pushed it for further
clinical test.
CGP55845 is another GABAB receptor antagonist undergoing
preclinical study. In an aged rat model with impaired
cognition, treatment with CGP55845 completely reversed its
olfactory discrimination learning deficits and restored its
performance (Cryan and Kaupmann, 2005; Lasarge et al., 2009).
These results supported the potential importance of GABAB
receptor as the pharmaceutical target in cognition enhancing
activities.
OUTLOOK AND CONCLUSIONS
Although tremendous understanding of AD pathogenesis has
been achieved since last decade, there is still no effective
therapy to prevent, delay or stop the disease progression.
For a long time, inhibitory GABAergic interneurons and
GABA receptors were considered generally preserved in
AD, compared to the more vulnerable excitatory glutamate
and acetylcholine neurotransmission systems. However, in
recent years, abundant evidence has emerged to support the
notion that GABAergic signaling system undergoes pathological
alterations and contribute to AD pathogenesis. Accordingly,
targeting GABAergic neurotransmission is being explored as a
potential therapy for AD treatment. However, inconsistent and
controversial results have been reported, and these are likely
attributed by the complex pathological processes, limitations
of the animal models, and differences in the timing and
duration of the experimental design. Overall, we hope that
this review provides an overall of the current understanding
of the role of GABAergic inhibitory neurons in AD and calls
for the need of further investigating the GABAergic system
in AD pathogenesis using more sophisticated models, rigorous
methods and advanced technology. In this review, we present
multiple lines of evidence that there is significant GABAergic
derangement in AD and that Aβ, tau and apoE4 all mediate
GABAergic dysfunction.
AUTHOR CONTRIBUTIONS
YL wrote the manuscript. HZ reviewed and edited the
manuscript. ZC contributed to the references organization. All
authors have read and approved the final manuscript.
ACKNOWLEDGMENTS
This work was supported by National Natural Science
Foundation of China (81301105).
REFERENCES
Atack, J. R. (2010). Preclinical and clinical pharmacology of the GABAA receptor
α5 subtype-selective inverse agonist α5IA. Pharmacol. Ther. 125, 11–26. doi: 10.
1016/j.pharmthera.2009.09.001
Atack, J. R., Maubach, K. A., Wafford, K. A., O’connor, D., Rodrigues, A. D.,
Evans, D. C., et al. (2009). In vitro and in vivo properties of 3-tert-butyl-7–(5-
methylisoxazol-3-yl)-2(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-
d]-[1,2,4]triazine (MRK-016), a GABAA receptor α5 subtype-selective
inverse agonist. J. Pharmacol. Exp. Ther. 331, 470–484. doi: 10.1124/jpet.109.
157636
Bareggi, S. R., Franceschi, M., Bonini, L., Zecca, L., and Smirne, S. (1982).
Decreased CSF concentrations of homovanillic acid and γ-aminobutyric
acid in Alzheimer’s disease. Age- or disease-related modifications?
Arch. Neurol. 39, 709–712. doi: 10.1001/archneur.1982.005102300
35010
Barnard, E. A., Skolnick, P., Olsen, R.W.,Mohler, H., Sieghart,W., Biggio, G., et al.
(1998). International union of pharmacology. XV. Subtypes of γ-aminobutyric
acidA receptors: classification on the basis of subunit structure and receptor
function. Pharmacol. Rev. 50, 291–313.
Bell, K. F., and Claudio Cuello, A. (2006). Altered synaptic function in Alzheimer’s
disease. Eur. J. Pharmacol. 545, 11–21. doi: 10.1016/j.ejphar.2006.06.045
Frontiers in Aging Neuroscience | www.frontiersin.org 8 February 2016 | Volume 8 | Article 31
Li et al. GABAergic Neurotransmission in Alzheimer’s Disease
Bell, K. F., de Kort, G. J., Steggerda, S., Shigemoto, R., Ribeiro-Da-Silva, A.,
and Cuello, A. C. (2003). Structural involvement of the glutamatergic
presynaptic boutons in a transgenic mouse model expressing early onset
amyloid pathology. Neurosci. Lett. 353, 143–147. doi: 10.1016/j.neulet.2003.
09.027
Bell, K. F., Ducatenzeiler, A., Ribeiro-Da-Silva, A., Duff, K., Bennett, D. A.,
and Cuello, A. C. (2006). The amyloid pathology progresses in a
neurotransmitter-specific manner. Neurobiol. Aging 27, 1644–1657. doi: 10.
1016/j.neurobiolaging.2005.09.034
Bormann, J. (2000). The ‘ABC’ of GABA receptors. Trends Pharmacol. Sci. 21,
16–19. doi: 10.1016/s0165-6147(99)01413-3
Bowery, N. (1989). GABAB receptors and their significance in mammalian
pharmacology. Trends Pharmacol. Sci. 10, 401–407. doi: 10.1016/0165-
6147(89)90188-0
Buggia-Prévot, V., Fernandez, C. G., Riordan, S., Vetrivel, K. S., Roseman, J.,
Waters, J., et al. (2014). Axonal BACE1 dynamics and targeting in hippocampal
neurons: a role for Rab11 GTPase. Mol. Neurodegener. 9:1. doi: 10.1186/1750-
1326-9-1
Caillet-Boudin, M. L., Buée, L., Sergeant, N., and Lefebvre, B. (2015). Regulation of
humanMAPT gene expression.Mol. Neurodegener. 10:28. doi: 10.1186/s13024-
015-0025-8
Chebib, M., and Johnston, G. A. (1999). The ‘ABC’ of GABA receptors: a brief
review. Clin. Exp. Pharmacol. Physiol. 26, 937–940. doi: 10.1046/j.1440-1681.
1999.03151.x
Collinson, N., Kuenzi, F. M., Jarolimek, W., Maubach, K. A., Cothliff, R., Sur, C.,
et al. (2002). Enhanced learning and memory and altered GABAergic synaptic
transmission in mice lacking the alpha 5 subunit of the GABAA receptor.
J. Neurosci. 22, 5572–5580.
Crestani, F., Keist, R., Fritschy, J. M., Benke, D., Vogt, K., Prut, L., et al.
(2002). Trace fear conditioning involves hippocampal α5 GABAA receptors.
Proc. Natl. Acad. Sci. U S A 99, 8980–8985. doi: 10.1073/pnas.1422
88699
Cryan, J. F., and Kaupmann, K. (2005). Don’t worry ‘B’ happy!: a role for GABAB
receptors in anxiety and depression. Trends Pharmacol. Sci. 26, 36–43. doi: 10.
1016/j.tips.2004.11.004
Cummings, D. M., André, V. M., Uzgil, B. O., Gee, S. M., Fisher, Y. E., Cepeda, C.,
et al. (2009). Alterations in cortical excitation and inhibition in genetic
mouse models of Huntington’s disease. J. Neurosci. 29, 10371–10386. doi: 10.
1523/JNEUROSCI.1592-09.2009
Dawson, G. R., Maubach, K. A., Collinson, N., Cobain, M., Everitt, B. J.,
Macleod, A. M., et al. (2006). An inverse agonist selective for α5 subunit-
containing GABAA receptors enhances cognition. J. Pharmacol. Exp. Ther. 316,
1335–1345. doi: 10.1124/jpet.105.092320
Drott, J., Desire, L., Drouin, D., Pando, M., and Haun, F. (2010). Etazolate
improves performance in a foraging and homing task in aged rats. Eur. J.
Pharmacol. 634, 95–100. doi: 10.1016/j.ejphar.2010.02.036
Farrant, M., and Nusser, Z. (2005). Variations on an inhibitory theme: phasic and
tonic activation of GABAA receptors. Nat. Rev. Neurosci. 6, 215–229. doi: 10.
1038/nrn1625
Filippini, N., Macintosh, B. J., Hough, M. G., Goodwin, G. M., Frisoni, G. B.,
Smith, S. M., et al. (2009). Distinct patterns of brain activity in young carriers of
the APOE-epsilon4 allele. Proc. Natl. Acad. Sci. U S A 106, 7209–7214. doi: 10.
1073/pnas.0811879106
Froestl, W., Gallagher, M., Jenkins, H., Madrid, A., Melcher, T., Teichman, S., et al.
(2004). SGS742: the first GABAB receptor antagonist in clinical trials. Biochem.
Pharmacol. 68, 1479–1487. doi: 10.1016/j.bcp.2004.07.030
Furukawa, K., and Mattson, M. P. (1998). Secreted amyloid precursor protein
alpha selectively suppresses N-methyl-D-aspartate currents in hippocampal
neurons: involvement of cyclic GMP. Neuroscience 83, 429–438. doi: 10.
1016/s0306-4522(97)00398-9
Gabriella, G., and Giovanna, C. (2010). γ-Aminobutyric acid type A GABAA
receptor subtype inverse agonists as therapeutic agents in cognition.
Methods Enzymol. 485, 197–211. doi: 10.1016/B978-0-12-381296-4.
00011-7
Garcia-Marin, V., Blazquez-Llorca, L., Rodriguez, J. R., Boluda, S., Muntane, G.,
Ferrer, I., et al. (2009). Diminished perisomatic GABAergic terminals on
cortical neurons adjacent to amyloid plaques. Front. Neuroanat. 3:28. doi: 10.
3389/neuro.05.028.2009
Gautam, V., D’avanzo, C., Berezovska, O., Tanzi, R. E., and Kovacs, D. M.
(2015). Synaptotagmins interact with APP and promote Aβ generation. Mol.
Neurodegener. 10:31. doi: 10.1186/s13024-015-0028-5
Getova, D. P., and Bowery, N. G. (2001). Effects of high-affinity
GABAB receptor antagonists on active and passive avoidance
responding in rodents with γ-hydroxybutyrolactone-induced absence
syndrome. Psychopharmacology 157, 89–95. doi: 10.1007/s002130
100766
Glenner, G. G., and Wong, C. W. (1984). Alzheimer’s disease and down’s
syndrome: sharing of a unique cerebrovascular amyloid fibril protein.
Biochem. Biophys. Res. Commun. 122, 1131–1135. doi: 10.1016/0006-291x(84)
91209-9
Glykys, J., Mann, E. O., and Mody, I. (2008). Which GABAA receptor subunits are
necessary for tonic inhibition in the hippocampus? J. Neurosci. 28, 1421–1426.
doi: 10.1523/JNEUROSCI.4751-07.2008
Glykys, J., andMody, I. (2007). The main source of ambient GABA responsible for
tonic inhibition in the mouse hippocampus. J. Physiol. 582, 1163–1178. doi: 10.
1113/jphysiol.2007.134460
Goate, A., Chartier-Harlin, M. C., Mullan, M., Brown, J., Crawford, F., Fidani, L.,
et al. (1991). Segregation of a missense mutation in the amyloid precursor
protein gene with familial Alzheimer’s disease. Nature 349, 704–706. doi: 10.
1038/349704a0
Golovyashkina, N., Penazzi, L., Ballatore, C., Smith, A. B., III, Bakota, L., and
Brandt, R. (2015). Region-specific dendritic simplification induced by Aβ,
mediated by tau via dysregulation of microtubule dynamics: a mechanistic
distinct event from other neurodegenerative processes. Mol. Neurodegener.
10:60. doi: 10.1186/s13024-015-0049-0
Gonzalez-Burgos, G., Rotaru, D. C., Zaitsev, A. V., Povysheva, N. V.,
and Lewis, D. A. (2009). GABA transporter GAT1 prevents spillover
at proximal and distal GABA synapses onto primate prefrontal
cortex neurons. J. Neurophysiol. 101, 533–547. doi: 10.1152/jn.911
61.2008
Goodman, Y., and Mattson, M. P. (1994). Secreted forms of β-amyloid
precursor protein protect hippocampal neurons against amyloid β-peptide-
induced oxidative injury. Exp. Neurol. 128, 1–12. doi: 10.1006/exnr.
1994.1107
Grouselle, D., Winsky-Sommerer, R., David, J. P., Delacourte, A., Dournaud, P.,
and Epelbaum, J. (1998). Loss of somatostatin-like immunoreactivity in
the frontal cortex of Alzheimer patients carrying the apolipoprotein
epsilon 4 allele. Neurosci. Lett. 255, 21–24. doi: 10.1016/s0304-3940(98)
00698-3
Gueli, M. C., and Taibi, G. (2013). Alzheimer’s disease: amino acid levels and
brain metabolic status. Neurol. Sci. 34, 1575–1579. doi: 10.1007/s10072-013-
1289-9
Guerrini, G., Ciciani, G., Cambi, G., Bruni, F., Selleri, S., Guarino, C., et al.
(2009). Synthesis, in vivo evaluation and molecular modeling studies of
new pyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide derivatives. Identification of a
bifunctional hydrogen bond area related to the inverse agonism. J. Med. Chem.
52, 4668–4682. doi: 10.1021/jm801599a
Guerrini, G., Ciciani, G., Costanzo, A., Daniele, S., Martini, C.,
Ghelardini, C., et al. (2013). Synthesis of novel cognition enhancers with
pyrazolo[5,1-c][1,2,4]benzotriazine core acting at gamma-aminobutyric acid
type A GABAA receptor. Bioorg. Med. Chem. 21, 2186–2198. doi: 10.1016/j.
bmc.2013.02.027
Guzmán, E. A., Bouter, Y., Richard, B. C., Lannfelt, L., Ingelsson, M., Paetau, A.,
et al. (2014). Abundance of Aβ5-x like immunoreactivity in transgenic 5XFAD,
APP/PS1KI and 3xTG mice, sporadic and familial Alzheimer’s disease. Mol.
Neurodegener. 9:13. doi: 10.1186/1750-1326-9-13
Hanger, D. P., Anderton, B. H., and Noble, W. (2009). Tau phosphorylation:
the therapeutic challenge for neurodegenerative disease. Trends Mol. Med. 15,
112–119. doi: 10.1016/j.molmed.2009.01.003
Hasegawa, M., Morishima-Kawashima, M., Takio, K., Suzuki, M., Titani, K.,
and Ihara, Y. (1992). Protein sequence and mass spectrometric analyses
of tau in the Alzheimer’s disease brain. J. Biol. Chem. 267, 170
47–17054.
Helm, K. A., Haberman, R. P., Dean, S. L., Hoyt, E. C., Melcher, T., Lund, P. K.,
et al. (2005). GABAB receptor antagonist SGS742 improves spatial memory
and reduces protein binding to the cAMP response element (CRE) in the
Frontiers in Aging Neuroscience | www.frontiersin.org 9 February 2016 | Volume 8 | Article 31
Li et al. GABAergic Neurotransmission in Alzheimer’s Disease
hippocampus. Neuropharmacology 48, 956–964. doi: 10.1016/j.neuropharm.
2005.01.019
Hu, J., Liu, C. C., Chen, X. F., Zhang, Y. W., Xu, H., and Bu, G. (2015).
Opposing effects of viral mediated brain expression of apolipoprotein E2
(apoE2) and apoE4 on apoE lipidation and Aβ metabolism in apoE4-
targeted replacement mice.Mol. Neurodegener. 10:6. doi: 10.1186/s13024-015-
0001-3
Hu, X., Li, X., Zhao, M., Gottesdiener, A., Luo, W., and Paul, S. (2014). Tau
pathogenesis is promoted by Aβ1–42 but not Aβ1–40.Mol. Neurodegener. 9:52.
doi: 10.1186/1750-1326-9-52
Huang, Y. (2010). Mechanisms linking apolipoprotein E isoforms with
cardiovascular and neurological diseases. Curr. Opin. Lipidol. 21, 337–345.
doi: 10.1097/MOL.0b013e32833af368
Huang, Y., and Mucke, L. (2012). Alzheimer mechanisms and therapeutic
strategies. Cell 148, 1204–1222. doi: 10.1016/j.cell.2012.02.040
Iqbal, K., Alonso Adel, C., Chen, S., Chohan, M. O., El-Akkad, E., Gong, C. X.,
et al. (2005). Tau pathology in Alzheimer disease and other tauopathies.
Biochim. Biophys. Acta 1739, 198–210. doi: 10.1016/j.bbadis.2004.
09.008
Iwakiri, M., Mizukami, K., Ikonomovic, M. D., Ishikawa, M., Abrahamson, E. E.,
DeKosky, S. T., et al. (2009). An immunohistochemical study of GABAA
receptor γ subunits in Alzheimer’s disease hippocampus: relationship to
neurofibrillary tangle progression. Neuropathology 29, 263–269. doi: 10.1111/j.
1440-1789.2008.00978.x
Jack, C. R., Jr., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W.,
Aisen, P. S., et al. (2013). Tracking pathophysiological processes in Alzheimer’s
disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol.
12, 207–216. doi: 10.1016/s1474-4422(12)70291-0
Jiang, S., Li, Y., Zhang, X., Bu, G., Xu, H., and Zhang, Y. W. (2014). Trafficking
regulation of proteins in Alzheimer’s disease. Mol. Neurodegener. 9:6. doi: 10.
1186/1750-1326-9-6
Jo, S., Yarishkin, O., Hwang, Y. J., Chun, Y. E., Park, M., Woo, D. H., et al.
(2014). GABA from reactive astrocytes impairs memory in mouse models of
Alzheimer’s disease. Nat. Med. 20, 886–896. doi: 10.1038/nm.3639
Johnston, G. A. (1994). Rand lecture, ASCEPT. GABA receptors: as complex as
ABC? Australaisian society for clinical and experimental pharmacologists and
toxicologists. Clin. Exp. Pharmacol. Physiol. 21, 521–526. doi: 10.1111/j.1440-
1681.1994.tb02550.x
Jung, J. I., Price, A. R., Ladd, T. B., Ran, Y., Park, H. J., Ceballos-Diaz, C., et al.
(2015). Cholestenoic acid, an endogenous cholesterol metabolite, is a potent
γ-secretase modulator. Mol. Neurodegener. 10:29. doi: 10.1186/s13024-015-
0021-z
Kanekiyo, T., Xu, H., and Bu, G. (2014). ApoE and Aβ in Alzheimer’s disease:
accidental encounters or partners? Neuron 81, 740–754. doi: 10.1016/j.neuron.
2014.01.045
Kehrer, C., Maziashvili, N., Dugladze, T., and Gloveli, T. (2008). Altered
excitatory-inhibitory balance in the NMDA-hypofunction model of
schizophrenia. Front. Mol. Neurosci. 1:6. doi: 10.3389/neuro.02.006.2008
Kleschevnikov, A. M., Belichenko, P. V., Villar, A. J., Epstein, C. J., Malenka, R. C.,
and Mobley, W. C. (2004). Hippocampal long-term potentiation suppressed
by increased inhibition in the Ts65Dn mouse, a genetic model of
down syndrome. J. Neurosci. 24, 8153–8160. doi: 10.1523/jneurosci.1766-
04.2004
Knoferle, J., Yoon, S. Y., Walker, D., Leung, L., Gillespie, A. K., Tong, L. M.,
et al. (2014). Apolipoprotein E4 produced in GABAergic interneurons causes
learning and memory deficits in mice. J. Neurosci. 34, 14069–14078. doi: 10.
1523/JNEUROSCI.2281-14.2014
Knust, H., Achermann, G., Ballard, T., Buettelmann, B., Gasser, R., Fischer, H.,
et al. (2009). The discovery and unique pharmacological profile of RO4938581
and RO4882224 as potent and selective GABAA α5 inverse agonists for the
treatment of cognitive dysfunction. Bioorg. Med. Chem. Lett. 19, 5940–5944.
doi: 10.1016/j.bmcl.2009.08.053
Kolarova, M., García-Sierra, F., Bartos, A., Ricny, J., and Ripova, D. (2012).
Structure and pathology of tau protein in Alzheimer disease. Int. J. Alzheimers
Dis. 2012:731526. doi: 10.1155/2012/731526
Lasarge, C. L., Bañuelos, C., Mayse, J. D., and Bizon, J. L. (2009). Blockade
of GABAB receptors completely reverses age-related learning impairment.
Neuroscience 164, 941–947. doi: 10.1016/j.neuroscience.2009.08.055
Lee, B. Y., Ban, J. Y., and Seong, Y. H. (2005). Chronic stimulation of
GABAA receptor with muscimol reduces amyloid β protein (25–35)-induced
neurotoxicity in cultured rat cortical cells. Neurosci. Res. 52, 347–356. doi: 10.
1016/j.neures.2005.04.008
Le Freche, H., Brouillette, J., Fernandez-Gomez, F. J., Patin, P., Caillierez, R.,
Zommer, N., et al. (2012). Tau phosphorylation and sevoflurane anesthesia:
an association to postoperative cognitive impairment. Anesthesiology 116,
779–787. doi: 10.1097/ALN.0b013e31824be8c7
Leung, L., Andrews-Zwilling, Y., Yoon, S. Y., Jain, S., Ring, K., Dai, J., et al.
(2012). Apolipoprotein E4 causes age- and sex-dependent impairments of hilar
GABAergic interneurons and learning and memory deficits in mice. PLoS One
7:e53569. doi: 10.1371/journal.pone.0053569
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J.,
Pettingell, W. H., et al. (1995). Candidate gene for the chromosome 1 familial
Alzheimer’s disease locus. Science 269, 973–977. doi: 10.1126/science.7638622
Li, G., Bien-Ly, N., Andrews-Zwilling, Y., Xu, Q., Bernardo, A., Ring, K.,
et al. (2009). GABAergic interneuron dysfunction impairs hippocampal
neurogenesis in adult apolipoprotein E4 knockin mice. Cell Stem Cell 5,
634–645. doi: 10.1016/j.stem.2009.10.015
Li, Y., Bohm, C., Dodd, R., Chen, F., Q11mar, S., Schmitt-Ulms, G., et al. (2014).
Structural biology of presenilin 1 complexes. Mol. Neurodegener. 9:59. doi: 10.
1186/1750-1326-9-59
Limon, A., Reyes-Ruiz, J. M., and Miledi, R. (2012). Loss of functional GABAA
receptors in the Alzheimer diseased brain. Proc. Natl. Acad. Sci. U S A 109,
10071–10076. doi: 10.1073/pnas.1204606109
Liu, D. S., Pan, X. D., Zhang, J., Shen, H., Collins, N. C., Cole, A. M., et al. (2015).
APOE4 enhances age-dependent decline in cognitive function by down-
regulating an NMDA receptor pathway in EFAD-Tg mice.Mol. Neurodegener.
10:7. doi: 10.1186/s13024-015-0002-2
Lonskaya, I., Hebron, M., Chen, W., Schachter, J., and Moussa, C. (2014).
Tau deletion impairs intracellular β-amyloid-42 clearance and leads to more
extracellular plaque deposition in gene transfer models. Mol. Neurodegener.
9:46. doi: 10.1186/1750-1326-9-46
Lüscher, B., and Keller, C. A. (2004). Regulation of GABAA receptor trafficking,
channel activity and functional plasticity of inhibitory synapses. Pharmacol.
Ther. 102, 195–221. doi: 10.1016/j.pharmthera.2004.04.003
Mahley, R. W., and Huang, Y. (2012). Apolipoprotein e sets the stage: response
to injury triggers neuropathology. Neuron 76, 871–885. doi: 10.1016/j.neuron.
2012.11.020
Mandelkow, E. M., and Mandelkow, E. (2012). Biochemistry and cell biology of
tau protein in neurofibrillary degeneration. Cold Spring Harb. Perspect. Med.
2:a006247. doi: 10.1101/cshperspect.a006247
Marcade, M., Bourdin, J., Loiseau, N., Peillon, H., Rayer, A., Drouin, D.,
et al. (2008). Etazolate, a neuroprotective drug linking GABAA receptor
pharmacology to amyloid precursor protein processing. J. Neurochem. 106,
392–404. doi: 10.1111/j.1471-4159.2008.05396.x
Marshall, F. H., White, J., Main, M., Green, A., and Wise, A. (1999). GABAB
receptors function as heterodimers. Biochem. Soc. Trans. 27, 530–535. doi: 10.
1042/bst0270530
Marttinen, M., Kurkinen, K. M., Soininen, H., Haapasalo, A., and Hiltunen, M.
(2015). Synaptic dysfunction and septin protein family members in
neurodegenerative diseases. Mol. Neurodegener. 10:16. doi: 10.1186/s13024-
015-0013-z
Mattson,M. P., Cheng, B., Culwell, A. R., Esch, F. S., Lieberburg, I., and Rydel, R. E.
(1993). Evidence for excitoprotective and intraneuronal calcium-regulating
roles for secreted forms of the beta-amyloid precursor protein. Neuron 10,
243–254. doi: 10.1016/0896-6273(93)90315-i
McQuail, J. A., Frazier, C. J., and Bizon, J. L. (2015). Molecular aspects of age-
related cognitive decline: the role of GABA signaling. Trends Mol. Med. 21,
450–460. doi: 10.1016/j.molmed.2015.05.002
Mitew, S., Kirkcaldie, M. T., Dickson, T. C., and Vickers, J. C. (2013). Altered
synapses and gliotransmission in Alzheimer’s disease and AD model mice.
Neurobiol. Aging 34, 2341–2351. doi: 10.1016/j.neurobiolaging.2013.04.010
Mizukami, K., Grayson, D. R., Ikonomovic, M. D., Sheffield, R., and
Armstrong, D. M. (1998). GABAA receptor β2 and β3 subunits mRNA in
the hippocampal formation of aged human brain with Alzheimer-related
neuropathology. Brain Res. Mol. Brain Res. 56, 268–272. doi: 10.1016/s0169-
328x(97)00347-1
Frontiers in Aging Neuroscience | www.frontiersin.org 10 February 2016 | Volume 8 | Article 31
Li et al. GABAergic Neurotransmission in Alzheimer’s Disease
Neumann, U., Rueeger, H., Machauer, R., Veenstra, S. J., Lueoend, R. M.,
Tintelnot-Blomley, M., et al. (2015). A novel BACE inhibitor NB-360
shows a superior pharmacological profile and robust reduction of Aβ and
neuroinflammation in APP transgenic mice.Mol. Neurodegener. 10:44. doi: 10.
1186/s13024-015-0033-8
Nilsen, L. H., Rae, C., Ittner, L. M., Götz, J., and Sonnewald, U. (2013). Glutamate
metabolism is impaired in transgenic mice with tau hyperphosphorylation.
J. Cereb. Blood Flow Metab. 33, 684–691. doi: 10.1038/jcbfm.
2012.212
Nykänen, N. P., Kysenius, K., Sakha, P., Tammela, P., and Huttunen, H. J. (2012).
gamma-Aminobutyric acid type A GABAA receptor activation modulates
tau phosphorylation. J. Biol. Chem. 287, 6743–6752. doi: 10.1074/jbc.m111.
309385
Ohki, Y., Shimada, N., Tominaga, A., Osawa, S., Higo, T., Yokoshima, S., et al.
(2014). Binding of longer Abeta to transmembrane domain 1 of presenilin 1
impacts on Abeta42 generation. Mol. Neurodegener. 9:7. doi: 10.1186/1750-
1326-9-7
Palop, J. J., Chin, J., Roberson, E. D., Wang, J., Thwin, M. T., Bien-Ly, N., et al.
(2007). Aberrant excitatory neuronal activity and compensatory remodeling
of inhibitory hippocampal circuits in mouse models of Alzheimer’s disease.
Neuron 55, 697–711. doi: 10.1016/j.neuron.2007.07.025
Parodi, J., Sepúlveda, F. J., Roa, J., Opazo, C., Inestrosa, N. C., and
Aguayo, L. G. (2010). β-amyloid causes depletion of synaptic vesicles leading
to neurotransmission failure. J. Biol. Chem. 285, 2506–2514. doi: 10.1074/jbc.
m109.030023
Pedersen, J. T., and Sigurdsson, E. M. (2015). Tau immunotherapy for Alzheimer’s
disease. Trends Mol. Med. 21, 394–402. doi: 10.1016/j.molmed.2015.03.003
Postina, R. (2012). Activation of alpha-secretase cleavage. J. Neurochem.
120(Suppl. 1), 46–54. doi: 10.1111/j.1471-4159.2011.07459.x
Potapenko, E. S., Biancardi, V. C., Zhou, Y., and Stern, J. E. (2013). Astrocytes
modulate a postsynaptic NMDA-GABAA-receptor crosstalk in hypothalamic
neurosecretory neurons. J. Neurosci. 33, 631–640. doi: 10.1523/jneurosci.3936-
12.2013
Querfurth, H. W., and LaFerla, F. M. (2010). Alzheimer’s disease. N. Engl. J. Med.
362, 329–344. doi: 10.1056/NEJMra0909142
Ramos-Miguel, A., Hercher, C., Beasley, C. L., Barr, A. M., Bayer, T. A.,
Falkai, P., et al. (2015). Loss of Munbc18–1 long splice variant in GABAergic
terminals is associated with cognitive decline and increased risk of dementia
in a community sample. Mol. Neurodegener. 10:65. doi: 10.1186/s13024-015-
0061-4
Rossor, M. N., Garrett, N. J., Johnson, A. L., Mountjoy, C. Q., Roth, M.,
and Iversen, L. L. (1982). A post-mortem study of the cholinergic and
GABA systems in senile dementia. Brain 105, 313–330. doi: 10.1093/brain/
105.2.313
Sadleir, K. R., Eimer, W. A., Cole, S. L., and Vassar, R. (2015). Aβ reduction in
BACE1 heterozygous null 5XFADmice is associated with transgenic APP level.
Mol. Neurodegener. 10:1. doi: 10.1186/1750-1326-10-1
Schweizer, C., Balsiger, S., Bluethmann, H., Mansuy, I. M., Fritschy, J. M.,
Mohler, H., et al. (2003). The γ 2 subunit of GABAA receptors is required for
maintenance of receptors at mature synapses.Mol. Cell. Neurosci. 24, 442–450.
doi: 10.1016/s1044-7431(03)00202-1
Selkoe, D. J. (1998). The cell biology of β-amyloid precursor protein and presenilin
in Alzheimer’s disease. Trends Cell Biol. 8, 447–453. doi: 10.1016/s0962-
8924(98)01363-4
Sepulveda, F. J., Parodi, J., Peoples, R. W., Opazo, C., and Aguayo, L. G. (2010).
Synaptotoxicity of Alzheimer β-amyloid can be explained by its membrane
perforating property. PLoS One 5:e11820. doi: 10.1371/journal.pone.00
11820
Shao, H., Zhang, Y., Dong, Y., Yu, B., Xia, W., and Xie, Z. (2014). Chronic
treatment with anesthetic propofol improves cognitive function and attenuates
caspase activation in both aged and Alzheimer’s disease transgenic mice.
J. Alzheimers Dis. 41, 499–513. doi: 10.3233/JAD-132792
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M.,
et al. (1995). Cloning of a gene bearing missense mutations in early-onset
familial Alzheimer’s disease. Nature 375, 754–760. doi: 10.1038/375754a0
Siopi, E., Llufriu-Dabén, G., Cho, A. H., Vidal-Lletjós, S., Plotkine, M.,
Marchand-Leroux, C. et al. (2008). Etazolate, an α-secretase activator,
reduces neuroinflammation and offers persistent neuroprotection following
traumatic brain injury inmice.Neuropharmacology 67, 183–192. doi: 10.1016/j.
neuropharm.2012.11.009
Song, L., Lu, S. X., Ouyang, X., Melchor, J., Lee, J., Terracina, G., et al.
(2015). Analysis of tau post-translational modifications in rTg4510 mice, a
model of tau pathology. Mol. Neurodegener. 10:14. doi: 10.1186/s13024-015-
0011-1
Spillantini, M. G., and Goedert, M. (1998). Tau protein pathology in
neurodegenerative diseases. Trends Neurosci. 21, 428–433. doi: 10.1016/s0166-
2236(98)01337-x
Stancu, I. C., Vasconcelos, B., Terwel, D., and Dewachter, I. (2014). Models
of β-amyloid induced Tau-pathology: the long and ‘‘folded’’ road to
understand the mechanism. Mol. Neurodegener. 9:51. doi: 10.1186/1750-
1326-9-51
Sun, B., Halabisky, B., Zhou, Y., Palop, J. J., Yu, G., Mucke, L., et al. (2009).
Imbalance between GABAergic and Glutamatergic transmission impairs adult
neurogenesis in an animal model of Alzheimer’s disease. Cell Stem Cell 5,
624–633. doi: 10.1016/j.stem.2009.10.003
Tapia-Rojas, C., Lindsay, C. B., Montecinos-Oliva, C., Arrazola, M. S.,
Retamales, R. M., Bunout, D., et al. (2015). Is L-methionine a trigger
factor for Alzheimer’s-like neurodegeneration?: changes in Aβ oligomers, tau
phosphorylation, synaptic proteins,Wnt signaling and behavioral impairment
in wild-type mice. Mol. Neurodegener. 10:62. doi: 10.1186/s13024-015-
0057-0
Tong, L. M., Djukic, B., Arnold, C., Gillespie, A. K., Yoon, S. Y., Wang, M. M.,
et al. (2014). Inhibitory interneuron progenitor transplantation restores
normal learning and memory in ApoE4 knock-in mice without or with Aβ
accumulation. J. Neurosci. 34, 9506–9515. doi: 10.1523/JNEUROSCI.0693-
14.2014
Tu, S., Okamoto, S., Lipton, S. A., and Xu, H. (2014). Oligomeric Aβ-induced
synaptic dysfunction in Alzheimer’s disease. Mol. Neurodegener. 9:48. doi: 10.
1186/1750-1326-9-48
Vellas, B., Sol, O., Snyder, P. J., Ousset, P. J., Haddad, R., Maurin, M., et al.
(2011). EHT0202 in Alzheimer’s disease: a 3-month, randomized, placebo-
controlled, double-blind study. Curr. Alzheimer Res. 8, 203–212. doi: 10.
2174/156720511795256053
Verret, L., Mann, E. O., Hang, G. B., Barth, A. M., Cobos, I., Ho, K., et al. (2012).
Inhibitory interneuron deficit links altered network activity and cognitive
dysfunction in Alzheimer model. Cell 149, 708–721. doi: 10.1016/j.cell.2012.02.
046
Wang, L., Cheng, S., Yin, Z., Xu, C., Lu, S., Hou, J., et al. (2015). Conditional
inactivation of Akt three isoforms causes tau hyperphosphorylation
in the brain. Mol. Neurodegener. 10:33. doi: 10.1186/s13024-015-
0030-y
Wang, X., Huang, T., Bu, G., and Xu, H. (2014). Dysregulation of protein
trafficking in neurodegeneration. Mol. Neurodegener. 9:31. doi: 10.1186/1750-
1326-9-31
Whittington, R. A., Bretteville, A., Dickler, M. F., and Planel, E. (2013). Anesthesia
and tau pathology. Prog. Neuropsychopharmacol. Biol. Psychiatry 47, 147–155.
doi: 10.1016/j.pnpbp.2013.03.004
Wu, Z., Guo, Z., Gearing, M., and Chen, G. (2014). Tonic inhibition
in dentate gyrus impairs long-term potentiation and memory in an
Alzheimer’s [corrected] disease model. Nat. Commun. 5:4159. doi: 10.1038/
ncomms5159
Xu, Z., Xiao, N., Chen, Y., Huang, H., Marshall, C., Gao, J., et al. (2015).
Deletion of aquaporin-4 in APP/PS1 mice exacerbates brain Aβ accumulation
and memory deficits. Mol. Neurodegener. 10:58. doi: 10.1186/s13024-015-
0056-1
Yamada, K., Patel, T. K., Hochgräfe, K., Mahan, T. E., Jiang, H., Stewart, F. R., et al.
(2015). Analysis of in vivo turnover of tau in a mouse model of tauopathy.Mol.
Neurodegener. 10:55. doi: 10.1186/s13024-015-0052-5
Yamamoto, K., Miyoshi, T., Yae, T., Kawashima, K., Araki, H., Hanada, K.,
et al. (1994). The survival of rat cerebral cortical neurons in the presence
of trophic APP peptides. J. Neurobiol. 25, 585–594. doi: 10.1002/neu.4802
50510
Yoon, B. E., and Lee, C. J. (2014). GABA as a rising gliotransmitter. Front. Neural
Circuits 8:141. doi: 10.3389/fncir.2014.00141
Yoon, B. E., Woo, J., and Lee, C. J. (2012). Astrocytes as GABA-ergic and GABA-
ceptive cells. Neurochem. Res. 37, 2474–2479. doi: 10.1007/s11064-012-0808-z
Frontiers in Aging Neuroscience | www.frontiersin.org 11 February 2016 | Volume 8 | Article 31
Li et al. GABAergic Neurotransmission in Alzheimer’s Disease
Zhan, X. Q., Yao, J. J., Liu, D. D., Ma, Q., and Mei, Y. A. (2014). Aβ40 modulates
GABAA receptor α6 subunit expression and rat cerebellar granule neuron
maturation through the ERK/mTOR pathway. J. Neurochem. 128, 350–362.
doi: 10.1111/jnc.12471
Zhang, H., Ma, Q., Zhang, Y.-W., and Xu, H. (2012). Proteolytic processing of
Alzheimer’s β-amyloid precursor protein. J. Neurochem. 120, 9–21. doi: 10.
1111/j.1471-4159.2011.07519.x
Zhang, Y., Shao, H., Dong, Y., Swain, C. A., Yu, B., Xia, W., et al. (2014).
Chronic treatment with anesthetic propofol attenuates β-amyloid protein levels
in brain tissues of aged mice. Transl. Neurodegener. 3:8. doi: 10.1186/2047-
9158-3-8
Zhang, X., Yu, C. J., and Sisodia, S. S. (2015). The topology of pen-2, a
γ-secretase subunit, revisited: evidence for a reentrant loop and a single pass
transmembrane domain. Mol. Neurodegener. 10:39. doi: 10.1186/s13024-015-
0037-4
Zimmer, R., Teelken, A. W., Trieling, W. B., Weber, W., Weihmayr, T., and
Lauter, H. (1984). γ-aminobutyric acid and homovanillic acid concentration
in the CSF of patients with senile dementia of Alzheimer’s type. Arch. Neurol.
41, 602–604. doi: 10.1001/archneur.1984.04210080010005
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Li, Sun, Chen, Xu, Bu and Zheng. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution and reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Aging Neuroscience | www.frontiersin.org 12 February 2016 | Volume 8 | Article 31
